Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Clinical Trial Size in Orphan and Rare Diseases

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jan 26, 2024 1:27pm

119 Views

Post# 35847417

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Clinical Trial Size in Orphan and Rare Diseases

It has been shown that orphan/ rare disease trials have smaller sample sizes than non-rare disease trials. Indeed some orphan drugs were approved by the European Medicines Agency based on studies with as few as 12 patients.

https://ojrd.biomedcentral.com/articles/10.1186/s13023-017-0597-1

Drugs for common orphan indications were more often biomarker directed.

The rare disease market is set for major growth in the decade to come, and pharma companies are securing their footholds now.

https://www.pharmavoice.com/news/rare-disease-market-orphan-drug-pharma/642983/

<< Previous

Bullboard Posts

Next >>

DRI Healthcare stock drops 28% after executive changes